In our research project, we want to find out whether the study treatment IAG933 is safe and effective for people with advanced mesothelioma or other cancers with specific changes in certain cancer-related genes.
Aim of the study
The purpose of this study is to find out if IAG933 is safe and tolerable in adult study participants with advanced mesothelioma or other solid tumors. This is a first-in-human study conducted in multiple study centers with IAG933 as a single agent. The study will consist of two parts: a dose increase part, followed by a dose expansion part. In the escalation section, the highest safe dose of IAG933 and the corresponding treatment sequence are determined. For this purpose, IAG933 is administered in ascending doses to different groups of people until the appropriate dose is found. In the dose expansion part, further participants will be treated with the dose specified for IAG933 in the first part of the study. In this part, the antitumor effect of IAG933 is assessed in more detail.Who can take part?
1. patients aged at least 18 years of age with a confirmed diagnosis of advanced (inoperable or metastatic) mesothelioma or other solid tumors. 2. patients for whom no other therapy is available.Procedure
- If you give your consent to participate in the study, you will receive IAG933 as study treatment.
- Duration: You will participate in the study for as long as the investigator believes that you will benefit from the study treatment, unless you decide to stop the study treatment or withdraw from the study. Number of visits: You must visit the investigator regularly. The visits will be more frequent at the beginning of your participation in the study (up to 7 visits in the first month or 11 visits if you participate in the food group) and 2 to 4 visits in the second month. After that, there are only 1 to 2 visits per month.